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Introduction
Cellular expression of the CD34 antigen identifies a 
morphologically and immunologically heterogeneous cell 
population that is functionally characterized by its in vitro 
capability to generate clonal aggregates derived from early 
and late progenitors in hematopoiesis and its in vivo capac-
ity to reconstitute the myeloid hematopoietic system in a 
supralethally irradiated host.1 On the other hand, there are 
several recent reports that a certain CD34+ cells form coop-
erative vascular networks as endothelial progenitor cells,2 
and human CD34+ cells have been used in clinical trials for 
treatment of myocardial infarction.3 Furthermore, synergis-
tic actions of CD34+ hematopoietic cells and mesenchymal 
stem/progenitor cells in vascularizing bioengineered tis-
sues have been reported.4 Thus, CD34+ cells are important 
cells for vascularizing bioengineered tissues as well as 
transplantation of bone marrow. Bone marrow and periph-
eral blood are the sources of immature hematopoietic pre-
cursors identified as CD34+ cells. Large numbers of CD34+ 
cells can be obtained from massive marrow harvests, such 
as for transplantation purposes.1,5,6 A diagnostic marrow 
sample contains only a small number of CD34+ cells, while 
even fewer are present in the peripheral samples taken 
under steady-state conditions. Recently developed cell 
separation procedures such as panning, combination of 
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galactose-bound vinyl polymer and soybean agglutinin,7 and 
immunomagnetic beads allow for the recovery of a highly 
enriched CD34+ cell population.8 However, this is generally 
achieved through a specific and often unacceptable cell loss. 
In contrast, in vitro expansion of CD34+ cells may be of 
particular relevance for cell transplantation.
CD34+ cells undergo regulated proliferation, conserva-
tion, and differentiation in the bone marrow microenviron-
ment. Therefore, the cell pool can be preserved while 
allowing controlled cell proliferation and differentiation.9,10 
CD34+ cells are localized in stem cell niches and local area 
networks in the microenvironment, where they interact 
with the components of their niche, including stromal cells, 
extracellular matrix proteins, heparan sulfate proteogly-
cans, and cytokines. Regional variation in these compo-
nents within the hematopoietic microenvironment may 
create niches that are specific to cells at various stages of 
differentiation.11–13 However, the identity and structural 
characteristics of macromolecules that mediate the forma-
tion of these niches are not well known. In addition, a 
method for selecting ex vivo amplification of CD34+ cells 
from bone marrow has not yet been established.14
Human CD34+ cells proliferate and mature in semisolid 
media when stimulated with exogenous hematopoietic 
cytokines such as stem cell factor (SCF), thrombopoietin 
(Tpo), and Flt-3 ligand (Flt-3).15–18 They also proliferate in 
association with bone marrow–derived stromal cells,19,20 
although biologically active amounts of hematopoietic 
cytokines cannot be detected in stromal culture superna-
tants.18 It is possible that hematopoietic cytokines are synthe-
sized by stromal cells but remain bound to them and/or their 
extracellular matrix. In fact, it has been demonstrated that 
natural and recombinant hematopoietic cytokines, such as 
IL-3 and granulocyte macrophage colony–stimulating factor 
(GM-CSF), can be absorbed by heparan sulfate, the major 
sulfated glycosaminoglycan in bone marrow stroma.17,18 
Furthermore, SCF, Tpo, and Flt-3 bind to LH/P MP-coated 
plates. These cytokines, once bound, can be presented in 
their biologically active form to the CD34+ cells.19,20 Other 
studies have demonstrated that heparinoids (heparin, hep-
aran sulfate, and other heparin-like molecules) serve as 
cofactors to promote binding of SCF to high-affinity recep-
tors, thus enhancing its activity.19,20 These findings may have 
important implications for the use of heparinoids as biomate-
rials for selective ex vivo expansion of CD34+ cells.
Because heparin and low-molecular-weight heparin 
(LH) are known to interact with a variety of functional pro-
teins, such as growth factors, cytokines, extracellular 
matrix components, and adhesion molecules,21,22 heparin 
could be used as a therapeutic agent for various pathologi-
cal conditions in which these functional proteins are 
involved.23 However, high-dose heparin cannot be used 
because of the excessive risk of bleeding.24 In contrast, LH 
has pharmacological and practical advantages as well as 
low protein binding, which produces a low, stable, and 
predictable anticoagulant response, thereby obviating the 
need for laboratory monitoring for dose adjustment.25. In 
addition, one or two subcutaneous injections per day are 
sufficient to maintain therapeutic concentrations because of 
the long plasma half-life of LH.25
On the other hand, protamine, a purified mixture of pro-
teins obtained from fish sperms, neutralizes heparin and LH 
by forming a stable complex, which lacks anticoagulant 
activity.26 Protamine is also used clinically as an antidote to 
reverse the anticoagulant activity of heparin following car-
diopulmonary bypass and in cases of heparin-induced bleed-
ing.27 In this study, we used LH (for comparison with heparin) 
as a heparinoid, and protamine to prepare LH/P MPs.28 The 
purpose of this study is to evaluate LH/P MPs as a stem cell 
niche for the controlled release of hematopoietic cytokines, 
which stimulate the selective growth of CD34+ cells. We 
report here that CD34+ cells derived from mouse bone mar-
row exhibited a significantly higher proliferation on LH/P 
MP-coated plates in hematopoietic progenitor growth 
medium (HPGM) supplemented with adequate cytokines and 
4% fetal bovine serum (FBS) than those on uncoated plates
Materials and methods
Preparation of LH/P MPs
LH/P MPs were synthesized as described previously.28 
Briefly, 0.35 ml of protamine solution (10 mg/ml; Mochida 
Pharmaceutical Co., Tokyo, Japan) was added drop by drop 
to 0.7 ml of LH (fragmin solution: 6.4 mg/ml; Kissei 
Pharmaceutical Co., Tokyo, Japan) with vigorous vortexing 
for approximately 2 min. To maximize the production of 
microparticles, protamine and LH were mixed in a ratio of 
1:2 (vol:vol) in this study. The LH/P MPs solution (1.05 ml) 
was then washed twice with phosphate-buffered saline 
(PBS) to remove nonreactants, and finally adjusted to 1 ml 
with PBS. More than 6 mg of dry LH/P MPs was obtained 
from 1.05 ml of the LH/P MPs solution.
Binding of LH/P MPs onto plastic plates and 
preparation of LH/P MP-coated plates
Twelve-well culture plates (well area: 360 mm2; Sumitomo 
Bakelite Corp., Tokyo, Japan) were coated overnight at 4°C 
with 1 ml of 0.5 mg/ml LH/P MPs in the PBS solution. 
LH/P MPs solutions were removed from the wells by pipet-
ting. LH/P MPs were loosely bound to the plastic surface, 
and the unbound particles were easily washed away with 
PBS. The LH/P MPs were stably coated onto the plastic 
surface by air-drying the 12-well plate-bound LH/P MPs 
for 1 h on a clean bench (Figure 1).
Isolation of mouse FP-BMCs from femurs of 
mice
Bone marrow cells were isolated by flushing both femurs 
of a C57BL/6J mouse (Japan SLC, Inc., Tokyo, Japan), and Kishimoto S et al.  3
debris were eliminated by filtration through a 100 μm cell 
strainer (BD Biosciences Discovery Labware, Bedford, 
MA, USA). Furthermore, red blood cells and platelets were 
eliminated by density gradient centrifugation with Ficoll-
Paque (1.077 g/ml; Amersham Biosciences, Uppsala, 
Sweden) at 400 g for 30 min. Mouse FP-BMCs were sus-
pended in Dulbecco’s modiﬁed Eagle’s medium (DMEM) 
without FBS before culturing. These animal experiments 
were approved and performed in accordance with the 
guidelines for animal experimentation of the National 
Defense Medical College (Saitama, Japan).
Culture of FP-BMCs from mouse bone marrow
Prepared mouse FP-BMCs were plated at an initial density 
of about 100,000 cells/well on either 12-well tissue culture 
plates (Sumitomo Bakelite Corp., Tokyo, Japan) or LH/P 
MP-coated plates in 2.5 ml of HPGM (Lonza Japan Corp., 
Tokyo, Japan) supplemented with the indicated concentra-
tions of inactivated FBS (JRH Biosciences, Inc., KS, USA) 
containing antibiotics (100 U/ml penicillin G and 100 μg/
ml streptomycin), and the indicated concentrations of 
recombinant human SCF (Acris Corp., Hiddenhausen, 
Germany), Tpo (Acris Corp.), and Flt-3 (Acris Corp.). The 
cells were cultured at 37°C in an atmosphere of 5% CO2 
and 100% relative humidity for the indicated periods. 
Almost all mouse FP-BMCs were easily suspended in the 
medium by pipetting the cell cultures, and the number of 
cells was counted using a hemocytometer (Sigma-Aldrich, 
Tokyo, Japan). The culture medium was not changed dur-
ing the 8-day culture.
Selection of culture medium
Mouse FP-BMCs were plated on LH/P MP-coated plates 
using either one of the four types of basal media (Asahi 
Techno Glass Co., Tokyo, Japan) including DMEM, (RPMI-
1640), DMEM/Ham’s nutrient mixture F12 (DMEM/F12), 
and HPGM. Each medium was supplemented with 4% FBS, 
antibiotics (100 U/ml penicillin G and 100 μg/ml streptomy-
cin), and 1/2× cytokines (SCF (10 ng/ml), Tpo (20 ng/ml), 
and Flt-3 (20 ng/ml)). The concentrations of SCF (20 ng/ml), 
Tpo (40 ng/ml) and Flt-3 (40 ng/ml) in HPGM are repre-
sented as 1×.
Flow cytometry analyses
Cultured mouse FP-BMCs (approximately 1.0 × 105 cells) 
were suspended in 1 ml of stain buffer (FBS (10 ml) + PBS 
(40 ml) + NaN3 (0.5 g)) and centrifuged twice at 3000 rpm 
for 2 min to wash the cells. A 5-μl aliquot of Phycoerythrin 
PE-labeled anti-mouse CD34 (BD Biosciences Pharmingen, 
San Diego, CA, USA) was added to the pellet and incu-
bated in an ice bath at 4°C for 15 min. The cells were 
Figure 1.  Preparation of LH/P MP-coated plates. LH aqueous (6.4 mg/ml) and protamine solutions (10 mg/ml) were mixed in a ratio 
of 1:2 (vol:vol) to produce LH/P MPs. The LH/P MPs consist of insoluble round complexes of approximately 1.0–0.5 μm in diameter 
(average: approximately 0.7 μm in diameter) and can be stably coated onto plastic surfaces by drying.4  Journal of Tissue Engineering 2(1)
washed twice with 1 ml of stain buffer, and then 500 μl of 
IsoFlow (Beckman Coulter, Fullerton, CA, USA) was 
added to the pellet. The samples were analyzed using 
EPICS®XL (Beckman Coulter).
Statistical analyses
Statistical analyses were performed by Student’s t-test. 
Probability values were calculated using the software, Stat 
Mate III for Windows (ATMS Co., Tokyo, Japan). The 
values of p < 0.05 were considered to be statistically 
significant.
Results
LH/P MP-coating and determination of culture 
conditions for expansion of CD34+ cells
Although added LH/P MPs were loosely bound to the plas-
tic surface, particles were easily washed away from the sur-
face with PBS. Alternatively, LH/P MPs were stably coated 
onto the plastic surface by air-drying bound LH/P MPs for 
1 h on a clean bench (Figure 1). While most FP-BMCs did 
not bind to both the LH/P MP-coated and uncoated tissue 
culture plates, only a small number of cells (<20%) loosely 
bound to both the LH/P MP-coated and uncoated tissue cul-
ture plates. Almost all of these bound cells could be easily 
released by washing with the culture medium.
The optimal concentrations of SCF, Tpo, Flt-3, and FBS 
in HPGM were tested for maximum expansion of mouse 
FP-BMCs and CD34+ cells on LH/P MP-coated plates 
(Figures 2 and 3). In this study, we used 12-well culture plates 
using 2.5 ml of the medium for culturing mouse FP-BMCs 
because over 50,000 cells were required to evaluate the 
marker CD34 by flow cytometry as well as for estimating the 
cell numbers. When mouse FP-BMCs (approximately 
100,000 cells) were plated on 12-well tissue culture plates, 
few cells adhered to the plates, and no cell colonies were 
obtained in these cultures. However, the optimal expansion 
of CD34+ cells as well as total cells (mouse FP-BMCs) was 
obtained on LH/P MP-coated tissue culture plates containing 
concentrations (1/2×) of SCF (10 ng/ml), Tpo (20 ng/ml), and 
Flt-3 (20 ng/ml) in HPGM supplemented with 4% FBS 
(Figure 2). The total cell number increased 4.6-fold under 
these conditions after 5 days of culture (Figure 2C). Because 
flow cytometry analysis (Figure 2B) revealed that 23.8% of 
original mouse FP-BMCs and 33.4% of the expanded cells 
after 5 days of culture were CD34+, CD34+ cells were esti-
mated to have increased 6.5-fold after 5 days of culture 
(Figure 2A).
Since FBS was required for expansion of cells, the opti-
mal concentration of FBS was also determined in the pres-
ence of the cytokines (1/2×), SCF (10 ng/ml), Tpo (20 ng/ml), 
and Flt-3 (20 ng/ml) in HPGM (Figure 3). The total cell 
Figure 2.  Optimal concentrations of cytokines. Optimal 
concentrations of SCF/Tpo/Flt-3 were determined on LH/P 
MP-coated plates incubated for 3 and 5 days in the presence of 
the indicated cytokines in HPGM supplemented with 4% FBS. 
The concentrations of SCF (20 ng/ml), Tpo (40 ng/ml), and Flt-3 
(40 ng/ml) in HPGM are represented as 1×. White bars (Day 3) 
and black bars (Day 5) represent total cells (mouse FP-BMCs) 
(C) and CD34+ cells (A), which were calculated using data from 
flow cytometry analyses shown in (B). The ratio of CD34+ to 
total cells is represented in (B). Data represent mean ± SD of 
six determinations.Kishimoto S et al.  5
(mouse FP-BMCs) number increased 3.3-fold by 4% or 
more FBS after 5 days of culture (Figure 3C). Since flow 
cytometry analysis (Figure 3B) revealed that 23.8% of orig-
inal mouse FP-BMCs and 39.0% of the expanded cells after 
5 days of culture were CD34+, CD34+ cells were estimated 
to have expanded 5.5-fold after 5 days of culture (Figure 
3A). Considering mouse FP-BMC growth and the ratio of 
CD34+ cells to the total cells, we chose concentrations 
(1/2×) of SCF (10 ng/ml), Tpo (20 ng/ml), and Flt-3 (20 ng/
ml) in HPGM supplemented with 4% FBS for optimal cul-
ture conditions for CD34+ cells on LH/P MP-coated plates.
Evaluation of various culture media for 
growth of CD34+ cells
To define the optimal media for expansion of CD34+ cells, 
mouse FP-BMCs were plated on LH/P MP-coated tissue 
culture plates containing various basal culture media, 
including DMEM, RPMI-1640, DMEM/F12, and HPGM 
supplemented with 4% FBS, antibiotics, and 1/2× cytokines 
(SCF (10 ng/ml), Tpo (20 ng/ml), and Flt-3 (20 ng/ml)). 
The CD34+ cells as well as mouse FP-BMCs were able to 
grow only in HPGM (Figure 4).
Assessment of expansion of CD34+ cells
When mouse FP-BMCs were plated on both LH/P 
MP-coated and uncoated tissue culture plates, the cells did 
not adhere to either of the plates. However, these cells were 
able to grow in suspension culture with concentrations 
(1/2×) of SCF (10 ng/ml), Tpo (20 ng/ml), and Flt-3 (20 ng/
ml) in HPGM supplemented with 4% FBS. The total cell 
number increased by 4.6- and 2.9-fold after 8 days of cul-
ture on LH/P MP-coated and uncoated tissue culture plates, 
respectively (Figure 5C). Since flow cytometry analysis 
revealed that 23.8% of initial mouse FP-BMCs, and 57.4% 
and 47.5% of the expanded cells on LH/P MP-coated and 
uncoated tissue culture plates, respectively, were CD34+ 
(Figure 5B), CD34+ cells were estimated to have expanded 
11.0-fold after 8 days of culture on LH/P MP-coated plates 
(Figure 5A). The ratios of CD34+ cells to total cells on 
LH/P MP-coated plates were always higher than those on 
uncoated plates as determined on Days 2, 4, and 8.
Discussion
We previously reported that LH/P MPs, which are approxi-
mately 1 μm in diameter, facilitate the fibroblast growth 
factor-2 (FGF-2) injection.28 FGF-2-containing LH/P MPs 
induce substantial vascularization and fibrous tissue forma-
tion because of the gradual release of FGF-2 molecules from 
the LH/P MPs. In this study, LH/P MP-coating as a stem cell 
niche stimulated the growth of CD34+ cells in HPGM with 
adequate cytokines (SCF, Tpo, and Flt-3). Mouse FP-BMCs 
in the presence of concentrations (1/2×) of cytokines (SCF 
(10 ng/ml), Tpo (20 ng/ml), and Flt-3 (20 ng/ml)) in HPGM 
supplemented with 4% FBS exhibited 4.6- and 2.4-fold 
Figure 3.  Optimal concentrations of serum. Optimal 
concentrations of FBS were determined on LH/P MP-coated 
plates incubated for 3 and 5 days in the presence of the 
indicated concentrations of FBS with 1/2× cytokines in HPGM. 
White bars (Day 3) and black bars (Day 5) represent total 
cells (mouse FP-BMCs) (C) and CD34+ cells (A), which were 
calculated using data from flow cytometry analyses shown in 
(B). The ratio of CD34+ to total cells is represented in (B). Data 
represent mean ± SD of six determinations.6  Journal of Tissue Engineering 2(1)
expansion after 8 days of culture on LH/P MP-coated and 
uncoated tissue culture plates, respectively. Furthermore, 
since flow cytometry analysis (Figure 5B) revealed that the 
percentage of CD34+ in the expanding cells on LH/P 
MP-coated plates increased from 23.8% to 57.4% during the 
8 days of culture (Figure 5B), the CD34+ cells expanded 
11.0- and 5.8-fold after 8 days of culture on LH/P MP-coated 
and uncoated tissue culture plates, respectively. Thus, the 
LH/P MP-coated plate in the presence of appropriate 
cytokines is a useful culture method for selective expansion 
of CD34+ cells in mouse FP-BMCs. However, we still need 
to characterize the expanded cell population with respect to 
various surface antigens in addition to CD34 and different 
morphologies/functions in the expanded cells.
CD34+ cells are localized in stem cell niches and local 
area networks in the microenvironment of bone marrow, 
where they interact with components of their niche includ-
ing stromal cell surfaces, extracellular matrix proteins, hep-
aran sulfate proteoglycans, and cytokines.17,18 Heparan 
sulfate proteoglycans are found in the extracellular matrix 
produced by stromal cells. They are prime candidates for 
selectively retaining CD34+ cells stimulatory factors in the 
niche (stromal layers), and they may regulate hematopoie-
sis.19 In addition, the immobilization of cytokines (SCF, 
Tpo, and Flt-3) onto LH/P MP-coated plates may provide a 
matrix-like stem cell niche that is bioactive for the prolif-
eration of CD34+ cells.
It is recognized in polymer chemistry that positively and 
negatively charged polymers interact ionically.29 Basic pro-
tamine molecules complexed with acidic molecules such as 
LH form microparticles through ionic interactions. The 
amounts of LH and protamine on the LH/P MP-coated 
plates used for culturing CD34+ cells did not alter for at 
least 8 days (data not shown). However, it probably appears 
that polypeptides such as SCF, Tpo, and Flt-3, once bound 
to the LH/P MPs are gradually released from the LH/P 
MP-coated plates and decreased by half within 5 days of 
culture.19 Although LH/P MPs are not biodegradable in 
vitro, the inclusion of various cytokines, such as SCF, Tpo, 
and Flt-3, into the coating will provide an excellent 
cytokine-containing matrix for CD34+ cells.15–18 We have 
previously demonstrated that SCF, Tpo, and Flt-3 are hepa-
rin-binding proteins, that all three interact with LH/P MPs, 
and that the immobilized cytokines are gradually released 
Figure 4.  Evaluation of various culture media for growth of 
CD34+ cells. To define the optimal media for expansion of 
CD34+ cells, mouse FP-BMCs were plated on LH/P MP-coated 
tissue culture plates containing various basal culture media 
supplemented with 4% FBS, antibiotics, and 1/2× cytokines. Data 
represent mean ± SD of six determinations.
Figure 5.  Expansion of CD34+ cells on LH/P MP-coated plates. 
Expansion of total cells (mouse FP-BMCs) and CD34+ cells on 
both LH/P MP-coated and uncoated tissue culture plates was 
examined in HPGM supplemented with 1/2× cytokines and 4% FBS 
for 8 days. Total cells (C) were counted using a hemocytometer, 
and CD34+ cells (A) were calculated using flow cytometry data 
(B) to determine the ratio of CD34+ cells to total cells (mouse  
FP-BMCs). Data represent mean ± SD of six determinations.Kishimoto S et al.  7
into the culture medium over 6 days.19,20 Furthermore, it 
has been shown that heparin addition enhances the expan-
sion of cord blood hematopoietic progenitor cells in three-
dimensional coculture with stromal cells.30
The induction of hematopoietic cell differentiations 
stimulated by several late-acting cytokines may be consid-
ered as consequence of proliferation of earlier hematopoi-
etic population such as CD34+ cells stimulated by several 
cytokines such as SCF and leukemia inhibitory factor 
(LIF).31 The majority of late-acting cytokines such as CSFs, 
interleukins (ILs), Tpo, and erythropoietin (EPO) support 
the proliferation and maturation of lineage-committed pro-
genitors and the functional properties of differentiated 
cells. Intermediate-acting, lineage-nonspecific cytokines 
including IL-3, IL-4, and GM-CSF are mainly directed 
toward progenitor cells in the intermediate stages of hemat-
opoietic development.32 Therefore, it may be possible that a 
specific hematopoietic population in BMCs can be selec-
tively expanded by various combinations of appropriate 
cytokines using the LH/P MP-coated plates.
Dalteparin is an LH that has an anticoagulant activity 
much lower than that of the native heparin and can therefore 
be administered subcutaneously.25,26 Therefore, dalteparin 
as LH was used to prepare LH/P MPs in these studies. No 
bleeding complications were observed in animals injected 
with LH/P MPs in a previous study.28 In addition, since the 
two components for LH/P MPs, LH, and protamine, are 
already in clinical use, their clinical safeties are ensured.
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